Although several targeted therapeutics such as vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) inhibitors have been approved for the treatment of metastatic disease over the past 10 years, metastatic RCC is still incurable [3]. This evidence concerns the gene MTOR and metastatic neoplasm.